A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

August 13, 2024

Study Completion Date

August 13, 2024

Conditions
Type 2 Diabetes
Interventions
DRUG

BGM0504 Administered SC

5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

DRUG

BGM0504 Administered SC

Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

DRUG

BGM0504 Administered SC

Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.

DRUG

Semaglutide Administered SC

"Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week"

DRUG

Placebo Administered SC

Placebo Comparator: Placebo Placebo administered SC once a week.

Trial Locations (1)

Unknown

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

BrightGene Bio-Medical Technology Co., Ltd.

INDUSTRY

NCT06974825 - A Study of BGM0504 in Chinese Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter